Catalogue Number: AB03833-10.3-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | LAT1; E16; MPE16; SLC7A5 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 0.1 mg |
| Host name: | Human |
| Clone: | 8-34B |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated by immunizing male 129S6/SvEv mice with human CD98 (huCD98)-expressing tumor cells. |
| Application: | FACS, FC, IHC, Inh, InVivoA, SPR |
SLC7A5
8140
Q01650
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
The murine version of the antibody inhibited tumor growth in Ramos xenografts and AML (OCI-AML-3) xenografts. Further, the chimeric version of the antibody was tested, confirming that also this version of the antibody could inhibit in vivo tumor growth with efficacy comparable to their parental counterparts. The antibody showed positive staining in 10/15 malignant melanomas and 4/18 lung cancers. In addition, the antibody gave positive staining in 6 of 6 frozen lung cancer samples and 2 of 2 frozen melanoma samples. Binding affinities of the murine and chimeric version of the antibody were determined using FACS analysis (Kd values between 0.9 nM and 4.5 nM). The chimeric antibody was also subjected to FACS analysis using three AML primary tumor samples and one cell line expressing cynomolgus monkey CD98 (cynCD98). The results demonstrated that the chimeric retained binding to human CD98 on AML cells and on cynCD98. The binding affinity of the murine, chimeric and humanized version of the antibody to CD98 was measured by surface plasmon resonance (JP2015501639A5).
This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.